Author

Peter Klaus Cornelius

SynDevRx (United States)ORCID 0009-0000-9448-3792Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Andrew J. DannenbergiD· 2 shared Benjamin A. MayesiD· 2 shared Bradley J. CarveriD· 2 shared James M. ShanahaniD· 2 shared John S. PeterseniD· 2 shared Pierre J. DufouriD· 2 shared David J. TurnquistiD· 1 shared Douglas V. GuzioriD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 34 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Andrew J. DannenbergORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyFrontiers in OncologyPeer-reviewedFeb 18, 2026

Evexomostat (SDX-7320), a Methionine Aminopeptidase Type 2 (METAP2) Inhibitor, Stimulates Weight Loss and Inhibits Obesity-Accelerated Tumor Growth

Peter Klaus Cornelius, Benjamin A. Mayes, Andrew J. Dannenberg…·Bradley J. Carver

This study shows that SDX-7320, a METAP2 inhibitor, reduces obesity-accelerated tumor growth in mice through both direct anti-tumor effects and indirect metabolic improvements.

DOI 10.3389/fonc.2026.1751681

mousebulk RNA-seq

𝕏 PostBluesky

Pharmacology & ToxicologyMolecular Cancer TherapeuticsPeer-reviewedMar 25, 2024

Pharmacological Characterization of SDX-7320/Evexomostat: a Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-Tumor and Anti-Metastatic Activity

Peter Klaus Cornelius, Benjamin A. Mayes, John S. Petersen…·Bradley J. Carver

This paper characterizes SDX-7320, a MetAP2 inhibitor, showing reduced CNS toxicity and improved pharmacokinetics compared to previous fumagillin derivatives.

6 citations

humanexperimental assay

𝕏 PostBluesky